Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders bought 29,275 call options on the stock. This represents an increase of approximately 43% compared to the average volume of 20,478 call options.
Recursion Pharmaceuticals Price Performance
Shares of NASDAQ RXRX traded down $0.44 during trading on Friday, hitting $5.28. The company had a trading volume of 31,496,533 shares, compared to its average volume of 16,582,415. The stock has a fifty day simple moving average of $4.81 and a two-hundred day simple moving average of $6.07. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -2.98 and a beta of 0.91. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the business earned ($0.39) EPS. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.
Institutional Trading of Recursion Pharmaceuticals
Several institutional investors have recently modified their holdings of RXRX. AlphaQuest LLC purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $36,000. GAMMA Investing LLC increased its position in shares of Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Analysts Set New Price Targets
Several research firms recently commented on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC restated a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $7.00.
Read Our Latest Stock Report on RXRX
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.